A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
HOME > BUSINESS
BUSINESS
- [Data] Sales of Mitsubishi Tanabe’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Taisho HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kyorin HD’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Shionogi’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Ono’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Santen’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kaken’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Mochida’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Nippon Shinyaku’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Zeria’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Kissei’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Fuso's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of ASKA's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Nippon Chemiphar's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Wakamoto's Mainstay Products in 1st Half of FY2012
December 13, 2012
- [Data] Sales of Torii’s Mainstay Products in 1st Half of FY2012
December 13, 2012
- Regulatory Challenges Remain for Introduction of Combination Vaccines: MSD VP Shirasawa
December 12, 2012
- Fycompa Approved for Use under NHS Scotland: Eisai
December 12, 2012
- Santen to Set Up Demand-Chain Strategic Planning Office
December 12, 2012
- Astellas, UMN Complete Administration of Seasonal Vaccine to Participants in Domestic PIII Trial
December 12, 2012
ページ
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…